AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial
Trial Will Investigate Company's Platform Cancer Immunotherapy in Patients with The Deadliest Form of Brain Cancer
IRVINE, Calif., June 20, 2018 -- (Healthcare Sales & Marketing Network) -- AIVITA Biomedical, a biotech company specializing in innovativ... Regenerative Medicine, Oncology, FDA AIVITA Biomedical, glioblastoma multiforme, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Immunotherapy | Marketing | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells